Nothing Special   »   [go: up one dir, main page]

Pihusch et al., 2006 - Google Patents

Endothelial cell–derived microparticles in allogeneic hematopoietic stem cell recipients

Pihusch et al., 2006

Document ID
7372628092047727938
Author
Pihusch V
Rank A
Steber R
Pihusch M
Pihusch R
Toth B
Hiller E
Kolb H
Publication year
Publication venue
Transplantation

External Links

Snippet

Background. Alterations of microparticles derived from different cell types are described in a number of diseases associated with inflammation and hemostatic disorders. Methods. In this prospective study, we firstly analyzed endothelial cell derived microparticles (EMP) in 19 …
Continue reading at journals.lww.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • C12N5/0087Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Pihusch et al. Endothelial cell–derived microparticles in allogeneic hematopoietic stem cell recipients
Donne et al. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Pêche et al. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection1
Spitzer et al. Combined histocompatibility leukocyte antigenmatched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism
Maury et al. CD4+ CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation
Goodman et al. DIRECT ACTIVATION OF PORCINE ENDOTHELIAL CELLS BY HUMAN NATURAL KILLER CELLS1
Perico et al. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy
Weng et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas
Li et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance
Whangbo et al. The role of regulatory T cells in graft-versus-host disease management
Kreisel et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion
Wolf et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation
Chan et al. NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
van den Brink et al. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity1
Paczesny et al. Acute graft-versus-host disease: new treatment strategies
Bishop et al. Approaching the promise of operational tolerance in clinical transplantation
US10106620B2 (en) Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
Kanda et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation
Sundin et al. Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?
Mueller Mechanisms of action of thymoglobulin
Craciun et al. Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease1
Nakai et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution
Mirzakhani et al. Immunological biomarkers of tolerance in human kidney transplantation: An updated literature review
MacDonald et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation
Hotta et al. Long-term nonhuman primate renal allograft survival without ongoing immunosuppression in recipients of delayed donor bone marrow transplantation